Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic has maintained a 'Buy' rating on Pulmonx (NASDAQ:LUNG) but lowered the price target from $20 to $12.
October 31, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity has maintained a 'Buy' rating on Pulmonx but lowered the price target from $20 to $12.
The news is directly related to Pulmonx and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowered price target may indicate a potential decrease in the stock's value. However, the impact on the stock price is uncertain in the short term as it depends on how investors interpret this information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100